The Government Accountability Office found major oversight problems with a controversial drug discount program for safety net hospitals.
The federal watchdog report requested by the House Energy and Commerce Committee comes amid increasing scrutiny of the program that mandates drug makers to provide discounts to safety net hospitals that provide care to low-income patients. The pharmaceutical industry has argued that the discount program, goes by the name 340B, has run rampant due to rapid expansion, while hospital groups charge that efforts to cut it will imperil care for low-income patients.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.